Related Experiment Video
Updated: May 20, 2025
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
CLDN18.2 CAR-derived Extracellular Vesicle Immunotherapy Improves Outcome in Murine Pancreatic Cancer
Yue Qing1,2,3, Ke Jiang1,2,3, Hua Jiang2,3,4
1Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Abstract:
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with no current effective treatment options. Chimeric antigen receptor (CAR) T cell therapy represents a powerful immunotherapeutic approach but faces major limitations in PDAC due to complex manufacturing and reduces efficacy within the highly immunosuppressive tumor microenvironment (TME). Small extracellular vesicles (sEVs) derived from CAR-T cells present a novel strategy to address these challenges. Here, CLDN18.2 CAR-T cells are used to generate CAR-sEVs via ultracentrifugation. The purified CAR-sEVs exhibit typical sEV size and morphology, containing established sEV markers, and carry functional CAR proteins along with cytotoxic molecules such as granzyme B. In vitro, CAR-sEVs displays potent cytotoxic activity against murine CLDN18.2+ PDAC cells, whereas no significant effects are observed in CLDN18.2- non-transformed cells. In an aggressive orthotopic murine PDAC model, CAR-sEV administration reduces tumor growth as measured by bioluminescence imaging and significantly extends survival. Notably, CAR-sEVs also significantly prolong survival compared to treatment with conventional CLDN18.2-targeting CAR-T cells, further supporting their therapeutic potential. Moreover, unlike CAR-T cells, CAR-sEVs do not induce systemic IL-6 release in vivo. These findings position CLDN18.2 CAR-sEVs as a promising therapeutic modality for PDAC, offering an innovative and potentially safer platform for solid tumor immunotherapy.
Insights
Small extracellular vesicles (sEVs) derived from chimeric antigen receptor (CAR) T cells show promise for treating pancreatic ductal adenocarcinoma (PDAC). CAR-sEVs effectively reduced tumor growth and extended survival in preclinical models, offering a potentially safer immunotherapy.
Area of Science:
- Oncology
- Immunotherapy
- Nanomedicine
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with limited treatment options.
- Chimeric antigen receptor (CAR) T cell therapy shows potential but faces challenges in PDAC, including manufacturing complexity and an immunosuppressive tumor microenvironment (TME).
- Small extracellular vesicles (sEVs) offer a novel therapeutic strategy to overcome CAR T-cell limitations.
Purpose of the Study:
- To investigate the therapeutic potential of CLDN18.2-specific CAR T-cell-derived small extracellular vesicles (CAR-sEVs) for pancreatic ductal adenocarcinoma (PDAC).
- To evaluate the efficacy and safety of CAR-sEVs in preclinical models of PDAC.
Main Methods:
- CLDN18.2 CAR-T cells were used to generate CAR-sEVs through ultracentrifugation.
- CAR-sEVs were characterized for size, morphology, marker expression, and functional cargo (CAR proteins, granzyme B).
- In vitro cytotoxicity assays were performed on CLDN18.2-positive PDAC cells and negative control cells.
- In vivo efficacy was assessed in an orthotopic murine PDAC model using bioluminescence imaging and survival studies.
Main Results:
- Purified CAR-sEVs exhibited characteristic sEV morphology and contained functional CAR proteins and cytotoxic molecules.
- CAR-sEVs demonstrated potent in vitro cytotoxicity against CLDN18.2+ PDAC cells, with no significant effect on CLDN18.2-negative cells.
- In vivo, CAR-sEV administration significantly reduced tumor growth and prolonged survival in a murine PDAC model compared to conventional CAR-T cells.
- CAR-sEVs did not induce systemic IL-6 release, suggesting improved safety over CAR-T cells.
Conclusions:
- CLDN18.2 CAR-sEVs represent a promising therapeutic strategy for PDAC.
- CAR-sEVs offer a potentially safer and effective alternative to CAR-T cell therapy for solid tumors.
- This approach provides an innovative platform for advancing immunotherapy in pancreatic cancer.
